Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PER2 | O15055 | 4/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | APEX1 | P27695 | 2/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL342227 | 0.98 | PER2 (0.45) | PER2PIK3CDL3MBTL1CHRM2CHRM5 | |
| SCHEMBL341356 | 0.95 | PIK3CD (0.47) | PER2PIK3CDCHRM2CHRM5CHRM1 | |
| SCHEMBL12032481 | 0.81 | PER2 (0.50) | PER2PIK3CDL3MBTL1CHRM2CHRM5 | |
| SCHEMBL26863358 | 0.79 | PER2 (0.49) | PER2PIK3CDL3MBTL1CHRM2CHRM5 | |
| SCHEMBL20762080 | 0.79 | PER2 (0.49) | PER2PIK3CDL3MBTL1CHRM2CHRM5 | |
| SCHEMBL13508581 | 0.79 | PER2 (0.49) | PER2PIK3CDL3MBTL1CHRM2CHRM5 | |
| SCHEMBL21401133 | 0.79 | PER2 (0.49) | PER2PIK3CDL3MBTL1CHRM2CHRM5 | |
| SCHEMBL25775398 | 0.75 | PER2 (0.46) | PER2PIK3CDL3MBTL1CHRM2CHRM5 | |
| SCHEMBL12228961 | 0.75 | PIK3CD (0.53) | PER2PIK3CDCHRM2CHRM5CHRM1 | |
| SCHEMBL2419806 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2651875-B1 | AMINES HAVING SECONDARY ALIPHATIC AMINO GROUPS | SIKA TECH AG (CH) | 2017-08-30 | — | — | EP | claimed |
| US-9290603-B2 | Amines having secondary aliphatic amino groups | SIKA TECHNOLOGY AG (CH) | 2016-03-22 | — | — | US | claimed |
| EP-2651875-A1 | AMINES HAVING SECONDARY ALIPHATIC AMINO GROUPS | Sika Technology AG (CH) | 2013-10-23 | — | — | EP | claimed |
| US-20130237681-A1 | AMINES HAVING SECONDARY ALIPHATIC AMINO GROUPS | SIKA TECHNOLOGY AG (CH) | 2013-09-12 | — | — | US | claimed |
| WO-2012080264-A1 | AMINES HAVING SECONDARY ALIPHATIC AMINO GROUPS | SIKA TECHNOLOGY AG (CH) | 2012-06-21 | — | — | WO | claimed |
| EP-2465842-A1 | Amines with secondary aliphatic amines | Sika Technology AG (CH) | 2012-06-20 | — | — | EP | claimed |
| US-8157950-B2 | Aldimine and composition containing aldimine | SIKA TECHNOLOGY AG (CH) | 2012-04-17 | — | — | US | claimed |
| US-20110253309-A1 | ALDIMINE AND COMPOSITION CONTAINING ALDIMINE | SIKA TECHNOLOGY AG (CH) | 2011-10-20 | — | — | US | claimed |
| EP-2194082-B1 | Aldimine and composition comprising aldimine | SIKA TECHNOLOGY AG (CH) | 2011-09-07 | — | — | EP | claimed |
| EP-2194082-A1 | Aldimine and composition comprising aldimine | Sika Technology AG (CH) | 2010-06-09 | — | — | EP | claimed |
| EP-2651875-B1 | AMINES HAVING SECONDARY ALIPHATIC AMINO GROUPS | SIKA TECH AG (CH) | 2017-08-30 | — | — | EP | disclosed |
| EP-2414418-B1 | COMPOSITION CURABLE IN TWO STAGES COMPRISING A SURFACE DEACTIVATED POLYISOCYANATE | SIKA TECH AG (CH) | 2017-08-09 | — | — | EP | disclosed |
| US-9290603-B2 | Amines having secondary aliphatic amino groups | SIKA TECHNOLOGY AG (CH) | 2016-03-22 | — | — | US | disclosed |
| US-9011630-B2 | Hot curing or heat-activated composition containing a surface-deactivated polyisocyanate | SIKA TECHNOLOGIES AG (CH) | 2015-04-21 | — | — | US | disclosed |
| US-8759455-B2 | Two-stage curable composition containing a surface-deactivated polyisocyanate | SIKA TECHNOLOGY AG (CH) | 2014-06-24 | — | — | US | disclosed |
| EP-2236535-A1 | Humidity curing polyurethane composition being accelerated by influence of heat | Sika Technology AG (CH) | 2010-10-06 | — | — | EP | disclosed |
| EP-2236533-A1 | Heat curing or heat activatable composition comprising a surface deactivated polyisocyanate | Sika Technology AG (CH) | 2010-10-06 | — | — | EP | disclosed |
| EP-2236534-A1 | Composition curable in two stages comprising a surface deactivated polyisocyanate | Sika Technology AG (CH) | 2010-10-06 | — | — | EP | disclosed |
| WO-2010063741-A1 | ALDIMINE AND COMPOSITION CONTAINING ALDIMINE | SIKA TECHNOLOGY AG (CH) | 2010-06-10 | — | — | WO | disclosed |
| EP-2194082-A1 | Aldimine and composition comprising aldimine | Sika Technology AG (CH) | 2010-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237681-A1 | AMINES HAVING SECONDARY ALIPHATIC AMINO GROUPS | AAAS, PNMT, PARG | PER2 3812/4885PIK3CD 2954/4885L3MBTL1 2466/4885 |
| US-20110253309-A1 | ALDIMINE AND COMPOSITION CONTAINING ALDIMINE | ALDH7A1, ALDH3A1, ADH5 | PER2 1482/4885PIK3CD 4204/4885L3MBTL1 1537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.